Co-Diagnostics, Inc. Common Stock (CODX)vsDexCom Inc (DXCM)
CODX
Co-Diagnostics, Inc. Common Stock
$1.12
+1.82%
HEALTHCARE · Cap: $8.31M
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 688737% more annual revenue ($4.97B vs $721,390). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).
CODX
Avoid33
out of 100
Grade: F
DXCM
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 30.8% YoY
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
2.0% revenue growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CODX
The strongest argument for CODX centers on Price/Book, Debt/Equity, EPS Growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : CODX
The primary concerns for CODX are Revenue Growth, Market Cap, Profit Margin.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
CODX profiles as a value stock while DXCM is a mature play — different risk/reward profiles.
CODX carries more volatility with a beta of 2.88 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 33/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Co-Diagnostics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?